Nasal Disinfectant 

Iogen’s I2 emollient formulations leverage the rapid bacteriocidal activity of molecular iodine to efficiently disinfect epidermal tissue, including the nares, without staining the skin.

Iogen’s I2 emollient formulations leverage the rapid bacteriocidal activity of molecular iodine to efficiently disinfect epidermal tissue, including the nares, without staining the skin.

Healthcare associated infections (HAIs) are infections patients can get while receiving medical treatment in a healthcare facility. One of the leading sources of HAIs is Staphylococcus aureus, a bacterium that roughly 30% of people carry in their nares. While most of the time S. aureus does not cause harm, S. aureus infections in healthcare settings can be serious. Antibiotic resistance compounds the severity of HAIs with Methicillin-resistant Staphylococcus aureus (MRSA) infections contributing to increased morbidity and mortality. Elimination of S. aureus (including MRSA) nasal carriage may be the most straightforward strategy to prevent the real and potential negative affects of S. aureus in the nasal cavity as well as other areas of the upper respiratory tract.

There are many established prophylactic and therapeutic procedures to eliminate topical pathogens and improve patient outcomes. These procedures include topical compositions, intravenous (IV) treatments, devices and other clinical procedures. However, nasal-borne Staphylococcus aureus (including MRSA) has not been effectively addressed. In a study of patients previously identified as MRSA carriers, 91% were positive for MRSA in nasal samples. The only approved treatment was Bactroban™ whose active agent is the antibiotic mupirocin. Mupirocin resistance was as high as 18% in 2002 and is estimated to be even higher today. This study underscores the need for alternative therapies to eliminate nasal-borne MRSA and that long-term use of antibiotics is a self-limiting strategy.

Iogen has developed an emollient preoperative, iodine-based nasal treatment that quickly and effectively decreases MRSA and S. aureus colonization in the nares reducing the risk of infection among surgery patients. Iogen provides at risk S. aureus carriers and non-carrier patients confidence prior to entering the surgical environment with a reduced risk of infection or developing antibiotic resistance. In contrast to other commercially available iodophors that are acidic and highly buffered, this clear nasal treatment is non-staining, has a neutral pH and is therefore not irritating.

Importantly, molecular iodine is highly microbicidal with no evidence of resistance during short- or long-term use. An in vitro study evaluating the antimicrobial effectiveness of molecular iodine, delivered as an iodophor, demonstrated a high degree of bacteriocidal efficiency among 10 genotypically different MRSA isolates. The broadspectrum activity of molecular iodine is enhanced by Iogen’s stabilizing emollient carriers. The increased solubility and prolonged activity of Iogen’s I2 emollient formulations leverages the rapid bacteriocidal activity of molecular iodine to efficiently disinfect epidermal tissue, including the nares, without staining the skin.